Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide development program for the Treatment of Septic Shock
September 4, 2019
Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and